Archive

2025

Browsing

Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration. Marks, who was instrumental in Operation Warp Speed and known for championing fast-tracked drug approvals, announced his departure on Friday, citing fundamental disagreements with Health…